Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Company Overview

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas. By leveraging its platform to validate novel targets and generate lead candidates, the company aims to address unmet medical needs where dysregulated lipid environments drive disease progression.

Headquartered in South San Francisco, California, Gyre Therapeutics was founded in 2021 and completed its initial public offering on the Nasdaq Global Market under the ticker symbol GYRE in mid-2023. Operating primarily in the United States, the company collaborates with academic researchers and industry partners to advance its discovery efforts. Through its innovative focus on membrane biochemistry, Gyre seeks to build a diversified portfolio of first-in-class small-molecule therapies.

Key Stats

• Today's Range: $7.51 to $7.87
• 50-Day Range: $6.65 to $8.28
• 52-Week Range: $6.11 to $19.00
• Volume: 59,132 shs
• Average Volume: 94,287 shs
• Market Capitalization: $726.18 million
• P/E Ratio: 754.75
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Gyre Therapeutics Stock Analysis - MarketRank™

Gyre Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 808th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Gyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Gyre Therapeutics has a consensus price target of $18.00, representing about 138.7% upside from its current price of $7.54.

Amount of Analyst Coverage

Gyre Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Gyre Therapeutics is 754.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 280.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gyre Therapeutics is 754.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 76.74.

Price to Book Value per Share Ratio

Gyre Therapeutics has a P/B Ratio of 7.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.88% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Gyre Therapeutics has recently decreased by 1.69%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gyre Therapeutics does not currently pay a dividend.

Dividend Growth

Gyre Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.88% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Gyre Therapeutics has recently decreased by 1.69%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.54

News Sentiment

Gyre Therapeutics has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Gyre Therapeutics this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for GYRE on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 10.00% of the stock of Gyre Therapeutics is held by insiders.

Percentage Held by Institutions

Only 23.99% of the stock of Gyre Therapeutics is held by institutions.

GYRE Stock Analysis - Frequently Asked Questions

How have GYRE shares performed this year?

Gyre Therapeutics' stock was trading at $12.10 on January 1st, 2025. Since then, GYRE stock has decreased by 37.7% and is now trading at $7.54.

How were Gyre Therapeutics' earnings last quarter?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted its quarterly earnings data on Monday, August, 11th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.01. The business had revenue of $26.77 million for the quarter, compared to the consensus estimate of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a trailing twelve-month return on equity of 7.67%.

Who are Gyre Therapeutics' major shareholders?

Top institutional shareholders of Gyre Therapeutics include Geode Capital Management LLC (0.43%), SBI Securities Co. Ltd. (0.25%), American Century Companies Inc. (0.01%) and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (0.01%). Insiders that own company stock include Songjiang Ma and Nassim Usman.
View institutional ownership trends.

How do I buy shares of Gyre Therapeutics?

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gyre Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GYRE
• Previous Symbol: NASDAQ:GYRE
• CIK: 1124105
• Web: www.catalystbiosciences.com
• Phone: (619) 949-3681
• Fax: 336-480-2107
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Gyre Therapeutics: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +139.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 752.75
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $12.09 million
• Net Margins: 4.08%
• Pretax Margin: 11.33%
• Return on Equity: 7.67%
• Return on Assets: 6.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.40
• Quick Ratio: 4.87

Sales & Book Value

• Annual Sales: $105.76 million
• Price / Sales: 6.85
• Cash Flow: $0.19 per share
• Price / Cash Flow: 40.00
• Book Value: $1.05 per share
• Price / Book: 7.16

Miscellaneous

• Outstanding Shares: 96,310,000
• Free Float: 86,682,000
• Market Cap: $724.25 million
• Optionable: No Data
• Beta: 1.86